西格玛受体连接体在实体中预防COVID死亡率:对未来治疗方法的影响
Reed L Berkowitz1, Andrew P Bluhm2,3, Glenn W Knox1
1Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
International journal of molecular sciences
|November 14, 2023
概括
新出现的冠状病毒需要新的治疗方法. 西格玛受体连接体和乳酸在感染SARS-CoV-2的小鼠中改善了生存率,提供了潜在的新型COVID-19疗法.
科学领域:
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 致命的冠状病毒定期出现,SARS-CoV-2变种对现有治疗方法表现出耐药性.
- 西格玛受体及其连接体通过破坏病毒复制显示出对SARS-CoV-2的潜在抗病毒作用.
- 重用FDA批准的药物为新型COVID-19治疗提供了一个具有成本效益的战略.
研究的目的:
- 调查西格玛受体对 SARS-CoV-2 诱导死亡率的影响.
- 为了评估一个试验中的抗病毒药物组合,包括一个西格玛受体连接体和一个免疫调节蛋白.
主要方法:
- 利用了ACE2-转基因小鼠与SARS-CoV-2进行了挑战.
- 服用西格玛-2受体配体,二胺和乳二来评估生存率和质量反弹.
- 在接受治疗的小鼠和模拟治疗的对照组中比较结果.
主要成果:
- 用西格玛-2受体连接体或迪芬胺和乳酸治疗的小鼠显示显著改善了生存率.
- 接受治疗的小鼠在SARS-CoV-2挑战后的体重迅速反弹.
- 研究结果表明,测试化合物对SARS-CoV-2具有保护作用.
结论:
- 西格玛受体连接体,特别是与乳二结合使用,显示出对抗SARS-CoV-2的治疗剂的前景.
- 迪芬胺和乳二烯的组合可能为COVID-19提供一个可行的治疗策略.
- 进一步的临床转化可能会导致SARS-CoV-2的新治疗和研究途径.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
734
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
734
01:12GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
01:29The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K